Investors

IR Overview

Press Releases

There are currently no events to display.
Date Title  
Toggle Summary Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients With Non-Small Cell Lung Cancer
PHILADELPHIA and OXFORD, England , July 2, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the
Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients With Non-Small Cell Lung Cancer
PHILADELPHIA and OXFORD, England , July 2, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted the
Toggle Summary Adaptimmune Announces Data From Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting
OXFORD, England and PHILADELPHIA , May 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program,
Adaptimmune Announces Data From Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting
OXFORD, England and PHILADELPHIA , May 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program,
Toggle Summary Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting
OXFORD, England and PHILADELPHIA , May 21, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data on its lead clinical program, an affinity
Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting
OXFORD, England and PHILADELPHIA , May 21, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data on its lead clinical program, an affinity
Toggle Summary Adaptimmune Announces New Additions to Senior Clinical Management
OXFORD, UK and PHILADELPHIA , May 20, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has augmented its senior management team with the additions of Lini Pandite, M.D.
Adaptimmune Announces New Additions to Senior Clinical Management
OXFORD, UK and PHILADELPHIA , May 20, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has augmented its senior management team with the additions of Lini Pandite, M.D.
Toggle Summary Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting
OXFORD, UK and PHILADELPHIA , May 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data at the 18th Annual American Society of Gene and Cell
Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting
OXFORD, UK and PHILADELPHIA , May 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data at the 18th Annual American Society of Gene and Cell
Toggle Summary Adaptimmune Announces Appointment of Vice President of Investor Relations
OXFORD, UK and PHILADELPHIA , May 12, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has strengthened its senior management team with the appointment of William (Will)
Adaptimmune Announces Appointment of Vice President of Investor Relations
OXFORD, UK and PHILADELPHIA , May 12, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has strengthened its senior management team with the appointment of William (Will)
Toggle Summary Adaptimmune Announces Closing of Initial Public Offering
OXFORD, UK and PHILADELPHIA , May 11, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP) today announced the closing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. The aggregate net proceeds to Adaptimmune, after
Adaptimmune Announces Closing of Initial Public Offering
OXFORD, UK and PHILADELPHIA , May 11, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP) today announced the closing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. The aggregate net proceeds to Adaptimmune, after
Toggle Summary Adaptimmune Announces Pricing of Initial Public Offering
OXFORD, United Kingdom and PHILADELPHIA, May 6, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ) today announced the pricing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS.
Adaptimmune Announces Pricing of Initial Public Offering
OXFORD, United Kingdom and PHILADELPHIA, May 6, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ) today announced the pricing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS.
Toggle Summary Adaptimmune appoints Lawrence M. Alleva to its Board of Directors
Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, today announces the appointment of Lawrence (Larry) M. Alleva, to its Board of Directors as an independent, non-executive director with immediate effect. Mr.
Adaptimmune appoints Lawrence M. Alleva to its Board of Directors
Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, today announces the appointment of Lawrence (Larry) M. Alleva, to its Board of Directors as an independent, non-executive director with immediate effect. Mr.
Toggle Summary Adaptimmune Strengthens Management Team with Key Executive Hires
Adaptimmune today announces that it has strengthened its senior management team with the appointment of Dr. Rafael Amado, as Chief Medical Officer, and Adrian (Ad) Rawcliffe, as Chief Financial Officer. Both appointments are effective from 16 March. Please click on the link below to download the
Adaptimmune Strengthens Management Team with Key Executive Hires
Adaptimmune today announces that it has strengthened its senior management team with the appointment of Dr. Rafael Amado, as Chief Medical Officer, and Adrian (Ad) Rawcliffe, as Chief Financial Officer. Both appointments are effective from 16 March. Please click on the link below to download the
Toggle Summary Adaptimmune Announces Interim Results from Pilot Trial of its Engineered NY-ESO T Cells
Adaptimmune announces the release of interim results from a pilot clinical trial 04511 of NY-ESOc259T which uses a patient’s own T cells that have been genetically altered to attack synovial sarcoma cells. Please click on the link below to download the full Press Release:- Adaptimmune Announces
Adaptimmune Announces Interim Results from Pilot Trial of its Engineered NY-ESO T Cells
Adaptimmune announces the release of interim results from a pilot clinical trial 04511 of NY-ESOc259T which uses a patient’s own T cells that have been genetically altered to attack synovial sarcoma cells. Please click on the link below to download the full Press Release:- Adaptimmune Announces
Toggle Summary Adaptimmune wins OBN Best New Biotech Development Programme of 2014
Adaptimmune has won the Best New Biotech Development Programme Award of 2014 at the OBN annual awards. The prestigious industry award recognizes Adaptimmune’s achievement in securing a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and
Adaptimmune wins OBN Best New Biotech Development Programme of 2014
Adaptimmune has won the Best New Biotech Development Programme Award of 2014 at the OBN annual awards. The prestigious industry award recognizes Adaptimmune’s achievement in securing a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and
Toggle Summary Adaptimmune secures $104 million in Series A Financing
Adaptimmune Limited, a leading biotechnology company focused on the use of T-cell therapy to treat cancer and infectious disease, today announced the completion of a $104 million Series A financing round.   Please click on the link below to download the full Press Release:-   Adaptimmune
Adaptimmune secures $104 million in Series A Financing
Adaptimmune Limited, a leading biotechnology company focused on the use of T-cell therapy to treat cancer and infectious disease, today announced the completion of a $104 million Series A financing round.   Please click on the link below to download the full Press Release:-   Adaptimmune
Toggle Summary FierceBiotech names Adaptimmune as one of its “Fierce 15” Biotech Companies of 2014
Adaptimmune today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Please click on the link below to download the full Press Release:- FierceBiotech
FierceBiotech names Adaptimmune as one of its “Fierce 15” Biotech Companies of 2014
Adaptimmune today announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Please click on the link below to download the full Press Release:- FierceBiotech
Toggle Summary Adaptimmune enters strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise novel cell-based therapies
Adaptimmune Limited, a leading biotechnology company developing TCR engineered T-cells to treat cancer, today announced that it has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialisation of its lead clinical cancer
Adaptimmune enters strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise novel cell-based therapies
Adaptimmune Limited, a leading biotechnology company developing TCR engineered T-cells to treat cancer, today announced that it has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialisation of its lead clinical cancer
Toggle Summary Bent Jakobsen speaking at AACR in San Diego
Bent Jakobsen, CSO to Adaptimmune, is presenting at AACR in San Diego on Tuesday 8th April, 3.00pm – 5.00pm in the session entitled: “CIMT-AACR-CIMM Joint Session on Deciphering and modulating T-cell specificity in clinically effective antitumor responses”
Bent Jakobsen speaking at AACR in San Diego
Bent Jakobsen, CSO to Adaptimmune, is presenting at AACR in San Diego on Tuesday 8th April, 3.00pm – 5.00pm in the session entitled: “CIMT-AACR-CIMM Joint Session on Deciphering and modulating T-cell specificity in clinically effective antitumor responses”
Toggle Summary Adaptimmune announces full-time appointment of James Noble as Chief Executive Officer
Adaptimmune Limited, the biotechnology company focused on the use of engineered T cells to treat cancer, today announced the full-time appointment of James Noble as Chief Executive Officer. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this
Adaptimmune announces full-time appointment of James Noble as Chief Executive Officer
Adaptimmune Limited, the biotechnology company focused on the use of engineered T cells to treat cancer, today announced the full-time appointment of James Noble as Chief Executive Officer. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this
Toggle Summary Adaptimmune announces award of £2.1m from the Biomedical Catalyst Fund
Adaptimmune has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy
Adaptimmune announces award of £2.1m from the Biomedical Catalyst Fund
Adaptimmune has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy
Toggle Summary Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
Adaptimmune today announces the release of interim results from a Phase I/II clinical trial using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. The study Chair presented these updated results today at the annual meeting of the American Society of
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
Adaptimmune today announces the release of interim results from a Phase I/II clinical trial using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. The study Chair presented these updated results today at the annual meeting of the American Society of
Toggle Summary Adaptimmune appoints Dr Jonathan Knowles as Chairman of the Board
Adaptimmune today announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect. Dr Knowles succeeds Nicholas Cross who has been Chairman of the company since foundation and will remain on the Board as Deputy Chairman.
Adaptimmune appoints Dr Jonathan Knowles as Chairman of the Board
Adaptimmune today announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect. Dr Knowles succeeds Nicholas Cross who has been Chairman of the company since foundation and will remain on the Board as Deputy Chairman.
Toggle Summary Adaptimmune Announces Opening of Phase I/IIa Clinical Trial in Ovarian Cancer
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif. Researchers will investigate the safety, bioactivity and
Adaptimmune Announces Opening of Phase I/IIa Clinical Trial in Ovarian Cancer
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif. Researchers will investigate the safety, bioactivity and
Toggle Summary Adaptimmune enters into Cell Therapy Manufacturing Services Agreement with NeoStem Subsidiary, Progenitor Cell Therapy
NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC (“PCT”), together with Adaptimmune Limited and Adaptimmune LLC (collectively, “Adaptimmune”), announced today a Services Agreement under which PCT will provide services to support Adaptimmune’s NYESO-1c259-T cell therapy
Adaptimmune enters into Cell Therapy Manufacturing Services Agreement with NeoStem Subsidiary, Progenitor Cell Therapy
NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC (“PCT”), together with Adaptimmune Limited and Adaptimmune LLC (collectively, “Adaptimmune”), announced today a Services Agreement under which PCT will provide services to support Adaptimmune’s NYESO-1c259-T cell therapy
Toggle Summary Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
(Atlanta, GA and Oxford, UK) 10 December, 2012.  Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.  Lead investigators for the study
Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
(Atlanta, GA and Oxford, UK) 10 December, 2012.  Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.  Lead investigators for the study
Toggle Summary Investigators to Present Preliminary Adaptimmune’s Findings for Gene Engineered T Cells in Myeloma
Adaptimmune announces the publication of dual abstracts in today’s issue of the Journal Blood, which report preliminary results from an early phase study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.  Lead investigators for the study will
Investigators to Present Preliminary Adaptimmune’s Findings for Gene Engineered T Cells in Myeloma
Adaptimmune announces the publication of dual abstracts in today’s issue of the Journal Blood, which report preliminary results from an early phase study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.  Lead investigators for the study will
Toggle Summary Adaptimmune is strengthening its Board
Adaptimmune announces New Board Appointments as clinical programmes get underway. Please click here for full Press Release
Adaptimmune is strengthening its Board
Adaptimmune announces New Board Appointments as clinical programmes get underway. Please click here for full Press Release
Toggle Summary Opening of Pilot Clinical Trial in Synovial Sarcoma
Adaptimmune announced today that it has opened a Pilot, open‐label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland. Please click here for Press Release  
Opening of Pilot Clinical Trial in Synovial Sarcoma
Adaptimmune announced today that it has opened a Pilot, open‐label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland. Please click here for Press Release  
Toggle Summary Opening of Phase I/II Clinical Trial for Metastatic Melanoma
Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.   Please click here for Press Release
Opening of Phase I/II Clinical Trial for Metastatic Melanoma
Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.   Please click here for Press Release
Toggle Summary Opening of Phase I/II Clinical Trial in Multiple Myeloma
Adaptimmune has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. Please click here for Press Release
Opening of Phase I/II Clinical Trial in Multiple Myeloma
Adaptimmune has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. Please click here for Press Release
Toggle Summary Adaptimmune announces launch of US Subsidiary
Adaptimmune Limited today announced that it has launched a US subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwen Binder-Scholl as Vice President of Operations of the new company. Please click on this link to download the full Press Release
Adaptimmune announces launch of US Subsidiary
Adaptimmune Limited today announced that it has launched a US subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwen Binder-Scholl as Vice President of Operations of the new company. Please click on this link to download the full Press Release
Toggle Summary Adaptimmune announces first ever clinical trial with engineered T cells designed to clear HIV infection
Oxford, UK and Philadelphia, PA: 7 October 2009. Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine announce the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever
Adaptimmune announces first ever clinical trial with engineered T cells designed to clear HIV infection
Oxford, UK and Philadelphia, PA: 7 October 2009. Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine announce the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever
Toggle Summary Press Release: Adaptimmune engineers immune cells able to clear HIV – clinical trials planned
Click below to download Press Release :- Adaptimmune Ltd Press Release – 09 Nov 2008
Press Release: Adaptimmune engineers immune cells able to clear HIV – clinical trials planned
Click below to download Press Release :- Adaptimmune Ltd Press Release – 09 Nov 2008
Toggle Summary Adaptimmune officially founded
Adaptimmune was officially founded on the 1st July 2008 with the remit of advancing the use of engineered T cell receptors in adoptive T cell therapy.
Adaptimmune officially founded
Adaptimmune was officially founded on the 1st July 2008 with the remit of advancing the use of engineered T cell receptors in adoptive T cell therapy.